|
Actelion ends development of asthma and SAR drug
Pharma Times Actelion has suffered a pipeline setback with the failure of its asthma and seasonal allergic rhinitis drug setipiprant in a mid-stage and a late-stage trial. The Swiss biotech says that it will "re-direct its development efforts in the … |
View full post on asthma – Google News